Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen Y, Ye F, et al. Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival. Eur Radiol. 2020;11. doi:10.1007/s00330-020-07460-x
   Google Scholar
• Llovet JM, Villanueva A, Marrero JA, et al. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology. 2020;20. doi:10.1002/hep.31327
   Google Scholar
• Shen Y, Wang H, Chen X, et al. Prognostic significance of lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization and radiofrequency ablation. Onco Targets Ther. 2019;12:7129–7137. doi:10.2147/OTT.S217935
   PubMed Web of Science ®Google Scholar
• Chen L-T, Martinelli E, Cheng A-L, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31:334–351. doi:10.1016/j.annonc.2019.12.001
   PubMed Web of Science ®Google Scholar
• Kim R, Kang TW, Cha DI, et al. Percutaneous cryoablation for perivascular hepatocellular carcinoma: therapeutic efficacy and vascular complications. Eur Radiol. 2019;29:654–662. doi:10.1007/s00330-018-5617-6
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a nonrandomised, open-label Phase 2 trial. Lancet Oncol. 2018;19:940–952. doi:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo B-Y, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193–202. doi:10.1200/JCO.19.01307
   PubMed Web of Science ®Google Scholar
• Taylor MH, Lee CH, Makker V, et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol. 2020;38:1154–1163. doi:10.1200/JCO.19.01598
   PubMed Web of Science ®Google Scholar
• Kawazoe A, Fukuoka S, Nakamura Y, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1057–1065. doi:10.1016/S1470-2045(20)30271-0
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38:2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Chen J, Hu X, Li Q, et al. Effectiveness and safety of toripalimab, camrelizumab and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Ann Transl Med. 2020;8:1187. doi:10.21037/atm-20-6063
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Chen R, et al. Plasma fibrinogen acts as a predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer: a retrospective study of 1004 Chinese breast cancer patients. BMC Cancer. 2021;21(1):542. doi:10.1186/s12885-021-08284-8
   PubMed Web of Science ®Google Scholar
• Xi-Wen Y, Hai-Jie H, Xiong X-Z, et al. The preoperative elevated plasma fibrinogen level is associated with the prognosis of hilar cholangiocarcinoma. Surg Today. 2021;2. doi:10.1007/s00595-021-02249-x
   Google Scholar
• Dai T, Deng M, Linsen Y, et al. Prognostic value of combined preoperative gamma-glutamyl transpeptidase to platelet ratio and fibrinogen in patients with HBV-related hepatocellular carcinoma after hepatectomy. Am J Transl Res. 2020;12(6):2984–2997.
   PubMed Web of Science ®Google Scholar
• Ji R, Ren Q, Bai S, et al. Prognostic significance of pretreatment plasma fibrinogen level in patients with digestive system tumors: a meta-analysis. Int J Biol Markers. 2018;33(3):254–265. doi:10.1177/1724600818773627
   PubMed Web of Science ®Google Scholar
• Liang Y-J, Mei X-Y, Zeng B, et al. Prognostic role of preoperative D-dimer, fibrinogen and platelet levels in patients with oral squamous cell carcinoma. BMC Cancer. 2021;21(1):122. doi:10.1186/s12885-021-07841-5
   PubMed Web of Science ®Google Scholar
• Kim JY, Kim TJ, Lee DK, et al. A preoperative risk prediction model for high malignancy potential gastrointestinal stromal tumors of the stomach. Surg Endosc. 2021;17. doi:10.1007/s00464-021-08501-2
   Google Scholar
• Erdem S, Amasyali AS, Aytac O, et al. Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics. Urol Oncol. 2014;32(7):1031–1040. doi:10.1016/j.urolonc.2014.03.013
   PubMed Web of Science ®Google Scholar
• Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: theBCLC staging classification. Semin Liver Dis. 1999;19:329–338. doi:10.1055/s-2007-1007122
   PubMed Web of Science ®Google Scholar
• UMLS metathesaurus - NCI_CTCAE (Common Terminology Criteria for Adverse Events 4.3 subset) - synopsis.” [Online]. Available from: https://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/NCI_CTCAE/index.html. Accessed February 14, 2020.
   Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. doi:10.1055/s-0030-1247132
   PubMed Web of Science ®Google Scholar
• Bharadwaj AG, Holloway RW, Miller VA, et al. Plasmin and plasminogen system in the tumor microenvironment: implications for cancer diagnosis, prognosis, and therapy. Cancers. 2021;13(8):1838. doi:10.3390/cancers13081838
   PubMed Web of Science ®Google Scholar
• Wang P-X, Wang H-J, Liu J-H, et al. A nomogram combining plasma fibrinogen and systemic immune‑inflammation index predicts survival in patients with resectable gastric cancer. Sci Rep. 2021;11(1):10301. doi:10.1038/s41598-021-89648-9
   PubMed Web of Science ®Google Scholar
• Rabizadeh E, Cherny I, Lederfein D, et al. The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development. Thromb Res. 2015;136(1):118–124. doi:10.1016/j.thromres.2014.11.023
   PubMed Web of Science ®Google Scholar
• Ghosh S, Nataraj NB, Noronha A, et al. PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR. Cell Rep. 2021;35(8):109181. doi:10.1016/j.celrep.2021.109181
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Harvey VS, Estrella P, et al. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest. 1987;57(6):673–686.
   PubMed Web of Science ®Google Scholar
• Wang X-P, Mao MJ, He Z-L, et al. A retrospective discussion of the prognostic value of combining prothrombin time (PT) and fibrinogen (Fbg) in patients with hepatocellular carcinoma. J Cancer. 2017;8(11):2079–2087. doi:10.7150/jca.19181.eCollection.2017
   PubMed Web of Science ®Google Scholar
• Dai T, Peng L, Lin G, et al. Preoperative elevated plasma fibrinogen level predicts tumor recurrence and poor prognosis in patients with hepatocellular carcinoma. J Gastrointest Oncol. 2019;10(6):1049–1063. doi:10.21037/jgo.2019.09.11
   PubMed Web of Science ®Google Scholar